Newsroom | 5385 results

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admiss...

WIXOM, Mich.--(BUSINESS WIRE)--This marks the 3rd consecutive year that Rockwell Medical earned this recognition—climbing the ranks from #50 (2024) and #40 (2025) to #16 (2026)....

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program’s largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l...

LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, announced today that it has named two accomplished healthcare leaders: Laurie Sicaeros as president of City of Hope Cancer Center Arizona and Melissa Childress as president of City of Hope Cancer Center Atlanta. Both leaders have built careers on improving patient access and strengthening healthcare systems in their communities. As cancer rates cont...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zag Bio™, Inc., a biotechnology company working to set a new standard for treating autoimmune disease, today announced it has advanced its lead program for Type 1 diabetes (T1D), ZAG-101, into clinical development. The company’s first-in-human Phase 1b/2a clinical trial (LANTERN) will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZAG-101 and explore its potential to preserve insulin-producing beta-cell function. “Advancing ZAG-101...

NEW YORK--(BUSINESS WIRE)--Ciba Health, a physician-led chronic care company focused on managing and preventing common and complex chronic diseases, today announced that its precision virtual care program is now a qualified solution on Mayo Clinic Platform. Designed to work alongside existing care teams, Ciba Health extends chronic disease management beyond the clinic for adults living with obesity, cardiometabolic diseases, digestive disorders, autoimmune conditions, and women's health conditi...

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi expands its UGA collaboration internationally with Universität Paderborn, increasing ai² platform capacity and strategic revenue opportunities....

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diab...